Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Background: Recently it has been reported that apremilast might promote melanogenesis and it would therefore not be safe to use this drug in patients with psoriasis who have a history of melanoma.
Methods: From January 2017 to December 2020, we retrospectively identified, within a cohort of 635 patients in follow-up care for melanoma, 16 cases of patients with psoriasis treated with apremilast and history of melanoma. Patients were monitored at our unit for a mean duration of 36 months of follow up.
Results: The use of apremilast, in our case series was, thus, effective in managing psoriasis without causing recurrence of previous melanoma or any new suspicious lesions which would need removal.
Discussion: It has been speculated that apremilast might not be safe in patients who have a history of melanoma as it would be involved in the stimulation of melanogenesis and consequent possibility of recurrence of previous melanoma.
Conclusion: Our data show that none of the patients treated with apremilast developed recurrence of melanoma at 36 months of follow-up. Further studies are necessary to confirm the safety of apremilast in a larger number of patients with concurrent malignancies, specifically melanoma, and for a longer follow-up period.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8884186 | PMC |
Publication Analysis
Top Keywords
Similar Publications
Usefulness of ultrasound in the assessment of the efficacy of apremilast in psoriatic arthritis: Articular, enthesitic and nail index.
Reumatol Clin (Engl Ed)
September 2025
Rheumatology Unit, Hospital Universitari Vall Hebron, Spain.
Background: Psoriatic arthritis (PsA) affects joints and entheses. The objective is to use ultrasound (US) to see inflammatory changes in joints and entheses in patients with active PsA starting Apremilast.
Primary Objective: 20% reduction in the US index (UIC) at 12 months.
Background: Central centrifugal cicatricial alopecia (CCCA) is a scarring alopecia primarily affecting Black women. To date, there are no standardized treatment regimens or approved medications for the treatment of CCCA. This single-center, open-label, clinical study investigated the efficacy of apremilast in the treatment of mild to moderate vertex-predominant CCCA.
View Article and Find Full Text PDFEffectiveness and Safety of Oral Apremilast in the Management of Oral Ulcers in Behcet's Disease: A Systematic Review.
Indian Dermatol Online J
September 2025
Department of Oral Medicine and Radiology, Dr. G. D. Pol Foundation Y.M.T. Dental College and Hospital, Maharashtra, India.
Background: Behçet's disease (BD) is a type of inflammatory disorder affecting multiple parts of the body. Apremilast is a selective inhibitor of the enzyme phosphodiesterase 4 (PDE4). The diminished inflammatory response by PDE4 inhibition is reported to offer a therapeutic benefit and clinical improvement in BD.
View Article and Find Full Text PDFA systematic review of tumor necrosis factor-α blockers, anti-interleukins, and small molecule inhibitors for dissecting cellulitis of the scalp treatment.
Orphanet J Rare Dis
May 2025
School of Medicine, Tehran University of Medical Sciences, Tehran, Iran.
Background: Dissecting cellulitis of the scalp (DCS) is a type of neutrophilic scarring alopecia identified by the development of folliculitis with clusters of perifollicular pustules and then progresses to abscesses and intercommunicating sinus formation. In the absence of evidence-based guidelines, the treatment of DCS remains a therapeutic challenge. Our study aimed to assess the safety and efficacy of biologics, including tumor necrosis factor-α (TNF-α) blockers, anti-interleukins (ILs), and small molecule inhibitors, including Janus kinase (JAK) inhibitors and phosphodiesterase inhibitors in treating DCS.
View Article and Find Full Text PDFEfficacy and Safety of Apremilast Over 52 Weeks in Patients with Plaque Psoriasis in High-Impact Areas and Impaired Quality of Life.
Dermatol Ther (Heidelb)
July 2025
Psoriasis-Center at the Department of Dermatology, University Medical Center Schleswig-Holstein, Campus Kiel, Kiel, Germany.
Introduction: In EMBRACE, significant benefits were seen with apremilast versus placebo on quality of life (QoL) and clinical outcomes after 16 weeks in patients with chronic plaque psoriasis in ≥ 1 high-impact area, limited skin involvement, and impaired QoL, in a European population previously unstudied with apremilast. Our objective was to evaluate the 52-week efficacy and safety of apremilast.
Methods: EMBRACE was a phase 4, multicenter, randomized, placebo-controlled, double-blind study.